吲哚布芬对2型糖尿病患者血小板聚集及凝血机制的影响

目的]观察吲哚布芬对2型糖尿病患者血小板聚集功能及凝血机制的影响.方法]分别以比浊法和凝固法检测应用吲哚布芬治疗前后2型糖尿病患者的血小板最大聚集率(MAR)和凝血全套各指标的变化.结果]经吲哚布芬治疗后,61例2型糖尿病患者活化部分凝血活酶时间(APTT)、纤维蛋白原凝固时间(FIBT)明显延长(P<0.05)...

Effect of Indobufen on Platelet Aggregation and Coagulation in Type 2 Diabetic Patients

Objective] To observe the effect of indobufen on platelet aggregation and coagulation of type 2 diabetic patients. Methods]The changes of maximal platelet aggregation（MAR） and indices of blood coagulation were observed before and after indobufen was used for the treatment of type 2 diabetic patients by using turbidimetry and freezing method. Results] After the treatment with indobufen, activated partial thromboplastin time（APTT） and fibrinogen clotting time（FIBT） of 61 patients with type 2 diabetes mellitus were pro- longed obviously（ P〈0.05）, while fibrinogen（FIB） and MAR induced by adenosine diphosphate（ADP）, collagen（Coil） and arachidonicacid（ACA） were decreased obviously（ P 〈0.05）. No change of prothrombin time （PT）, international normalized ratio（INR）, thrombin time（TT） and MAR induced by thrombin was found（ P 〉0.05）. Conclusion] Indobufen can inhibit platelet aggregation and improve the hemodynamics in type 2 dia- betic patients, and has no effect on PT, TT and INR. Therefore, it is safe and effective in anti-platelet aggregation treatment of type 2 diabetic patients.